A Phase 2a Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Adults With Asthma

NCT00783289 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

OTHER: Placebo
BIOLOGICAL: Benralizumab 25 mg
BIOLOGICAL: Benralizumab 100 mg
BIOLOGICAL: Benralizumab 200 mg

Sponsor

MedImmune LLC